Biogen chalks up a Tecfidera patent win in Europe after losing US protections

While Biogen’s attempts to resurrect a crucial Tecfidera patent in the U.S. floundered, the company is chalking up a win in Europe.

The European Commission has ruled that Biogen's multiple sclerosis drug Tecfidera will have market protections until February 2025, Biogen revealed in a filing.